Telix Pharmaceuticals reported group revenue of US$230 million in Q1 FY2016, up about 24% year-over-year from US$186 million. The sizable top-line growth indicates improving company fundamentals for the biotech firm and may support near-term stock performance.
Telix Pharmaceuticals reported group revenue of US$230 million in Q1 FY2016, up about 24% year-over-year from US$186 million. The sizable top-line growth indicates improving company fundamentals for the biotech firm and may support near-term stock performance.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
mildly positive
Sentiment Score
0.30
Ticker Sentiment
